Understanding Hologic (HOLX) Reliance on International Revenue
Have you evaluated the performance of
Hologic's
(HOLX) international operations for the quarter ending March 2025? Given the extensive global presence of this medical device maker, analyzing the patterns in international revenues is crucial for understanding its financial strength and potential for growth.
In the modern, closely-knit global economic landscape, the capacity of a business to access foreign markets is often a key determinant of its financial well-being and growth path. Investors now place great importance on grasping the extent of a company's dependence on international markets, as it sheds light on the firm's earnings stability, its skill in leveraging various economic cycles and its broad growth potential.
Presence in international markets can act as a hedge against domestic economic downturns and provide access to faster-growing economies. However, this diversification also brings complexities due to currency fluctuations, geopolitical risks and differing market dynamics.
While analyzing HOLX's performance for the last quarter, we found some intriguing trends in revenues from its overseas segments that Wall Street analysts commonly model and monitor.
The company's total revenue for the quarter stood at $1.01 billion, declining 1.2% year over year. Now, let's delve into HOLX's international revenue breakdown to gain insights into the significance of its operations beyond home turf.
During the quarter, Rest of World contributed $54.2 million in revenue, making up 5.39% of the total revenue. When compared to the consensus estimate of $54.31 million, this meant a surprise of -0.2%. Looking back, Rest of World contributed $55.2 million, or 5.40%, in the previous quarter, and $57 million, or 5.60%, in the same quarter of the previous year.
Of the total revenue, $146.5 million came from Europe during the last fiscal quarter, accounting for 14.57%. This represented a surprise of +7.94% as analysts had expected the region to contribute $135.73 million to the total revenue. In comparison, the region contributed $148.9 million, or 14.57%, and $137 million, or 13.46%, to total revenue in the previous and year-ago quarters, respectively.
Asia-Pacific generated $59.7 million in revenues for the company in the last quarter, constituting 5.94% of the total. This represented a surprise of -4.05% compared to the $62.22 million projected by Wall Street analysts. Comparatively, in the previous quarter, Asia-Pacific accounted for $59.8 million (5.85%), and in the year-ago quarter, it contributed $64.4 million (6.33%) to the total revenue.
Wall Street analysts expect Hologic to report a total revenue of $1.01 billion in the current fiscal quarter, which suggests a decline of 0.4% from the prior-year quarter. Revenue shares from Rest of World, Europe and Asia-Pacific are predicted to be 5.5%, 13.9% and 6.3%, corresponding to amounts of $55.2 million, $139.75 million and $63.53 million, respectively.
For the full year, a total revenue of $4.08 billion is expected for the company, reflecting an increase of 1.2% from the year before. The revenues from Rest of World, Europe and Asia-Pacific are expected to make up 5.4%, 13.9% and 6.1% of this total, corresponding to $219.98 million, $566.69 million and $247.84 million respectively.
Relying on international markets for revenues, Hologic faces both prospects and perils. Thus, tracking the company's international revenue trends is essential for accurately projecting its future trajectory.
In a world where international interdependencies and geopolitical conflicts are ever-increasing, Wall Street analysts closely monitor these trends for companies having international presence to adjust their earnings forecasts. Of course, there are several other factors, including a company's standing within its home borders, that influence analysts' earnings forecasts.
We at Zacks strongly focus on the dynamic earnings forecast of companies, given that empirical studies have demonstrated its potent impact on the immediate price movement of stocks. Invariably, there's a positive relationship -- upward earnings predictions often result in an increase in stock prices.
The Zacks Rank, our proprietary stock rating tool, comes with an externally validated impressive track record. It effectively utilizes shifts in earnings projections to act as a dependable barometer for forecasting short-term stock price trends.
Hologic, bearing a Zacks Rank #4 (Sell), is expected to underperform the broader market's movements in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Over the preceding four weeks, the stock's value has diminished by 0.1%, against an upturn of 9.1% in the Zacks S&P 500 composite. In parallel, the Zacks Medical sector, which counts Hologic among its entities, has appreciated by 1.4%. Over the past three months, the company's shares have seen a decline of 7% versus the S&P 500's 3.1% decline. The sector overall has witnessed a decline of 8.7% over the same period.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
Hologic, Inc. (HOLX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
